ALGS
NASDAQ · Biotechnology
Aligos Therapeutics Inc
$5.54
+0.03 (+0.54%)
Financial Highlights (FY 2026)
Revenue
1.37M
Net Income
-15,146,114
Gross Margin
—
Profit Margin
-1,106.7%
Rev Growth
-46.0%
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 53.4% | 53.4% |
| Operating Margin | -4,024.9% | -3,622.4% | -15.0% | -16.8% |
| Profit Margin | -1,106.7% | -1,051.4% | -16.0% | -16.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.37M | 2.54M | 10.09M | 11.15M |
| Gross Profit | — | — | 5.39M | 5.96M |
| Operating Income | -55,071,305 | -91,853,547 | -1,517,215 | -1,876,673 |
| Net Income | -15,146,114 | -25,262,236 | -1,613,644 | -1,815,730 |
| Gross Margin | — | — | 53.4% | 53.4% |
| Operating Margin | -4,024.9% | -3,622.4% | -15.0% | -16.8% |
| Profit Margin | -1,106.7% | -1,051.4% | -16.0% | -16.3% |
| Rev Growth | -46.0% | -46.0% | -9.4% | -9.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 46.3K | 46.3K | 3.40M | 3.50M |
| Total Equity | 17.16M | 17.16M | 25.89M | 24.88M |
| D/E Ratio | 0.00 | 0.00 | 0.13 | 0.14 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -54,500,020 | -95,950,739 | -2,029,249 | -2,356,621 |
| Free Cash Flow | — | — | -1,586,727 | -1,930,971 |